Nephrobesity is the evidence-based resource for nephro-obesity medicine — the emerging clinical field at the intersection of kidney disease and obesity. Source-bound, and built for clinicians who need the numbers, not the hype.
One discipline, four domains of expertise
Nephrobesity brings together the pharmacology, physiology, and clinical judgement needed when kidney disease and obesity coexist: incretin and cardio-reno-metabolic therapy with renal safety, the protein dilemma, obesity-related glomerulopathy, and the cardiovascular-kidney-metabolic (CKM) framework.
See the ten clinical domains → · The case for the discipline → · Evidence library →